Funding options, page-12

@oxxa23
Two somewhat different options,
1. a deal on the product MPS or distribution rights with equity or royalties on iPPS,
OR
2. CR across the board.

BRN went down the LDA route. A CR deal in which the company, say PAR, get the right to PUT shares to LDA at a discount to the Volume Weighted share price at the time. One advantage is smaller amounts can be obtained as needed. Another is LDA don't know when the put options will be exercised.
WBT have tried two methods, Firstly they offered deep-in-the-money options to be exercised a fair way out i think over six months So holders had plenty of time to look for progress. That worked well because the share price went up and it was profitable to sell shares and exercise. The reason the share price went up was that WBT were beating their milestones.
The second more typical approach was, after reaching some milestones, they did a standard CR. The share price had risen sharply. Then it fell sharply to the CR price. How come, you might ask --. (i wrote to ASIC - not about WBT they had nothing to gain.).

My preference is a deal on MPS, but i don't think it will get as much as needed to go all the way to Registration, but it might delay a CR until the price of PAR has risen.

Who else, BigPharma?. My erstwhile hope is CSL.

IMO. DYOR.